While it is frequently assumed that abrogating mutations such as indels and nonsense mutations (and probably missense mutations) are ubiquitous and homogeneous throughout tumors, immunohistochemical staining of tumors for BRG1 and BRM has shown that loss of expression has a variable penetrance in a given tumor (6). The gene discussed is SMARCA2; the disease is neoplasm.